Ticagrelor plasma concentration, metabolite ratio, and LDH level as independent risk factors for ticagrelor-induced dyspnea in ACS patients

1

The study identified independent risk factors for ticagrelor-induced dyspnea in patients with acute coronary syndrome.
2

Plasma levels of ticagrelor and its active metabolite, AR-C124910XX, were measured in 102 patients undergoing antiplatelet therapy.
3

Patients who developed dyspnea had significantly lower LDH levels and ticagrelor metabolite ratios compared to those who did not.
4

Higher peak concentrations of ticagrelor were associated with the occurrence of dyspnea, indicating a potential risk factor.
5

The study emphasizes the need for therapeutic drug monitoring of ticagrelor to manage the risk of dyspnea in ACS patients.

Frontiers In Cardiovascular Medicine

by Yazi Zhao, Mengqi Gong, Yong Su, Jiaxin Zhao, Fangde Hong, Zheyuan Lu, Mengqing Ma, Meijie Jiang, Youfeng Liang
June 23, 2026

1